Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Colorcon
Johnson and Johnson
AstraZeneca
Boehringer Ingelheim

Last Updated: January 29, 2020

DrugPatentWatch Database Preview

DALMANE Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Dalmane patents expire, and what generic alternatives are available?

Dalmane is a drug marketed by Valeant Pharm Intl and is included in one NDA.

The generic ingredient in DALMANE is flurazepam hydrochloride. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the flurazepam hydrochloride profile page.

Drug patent expirations by year for DALMANE
Recent Litigation for DALMANE

Identify potential future generic entrants

District Court Litigation
Case NameDate
Tyco Healthcare Group v. Mutual Pharmaceutical Co2013-05-06

See all DALMANE litigation

Synonyms for DALMANE
(E)-7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1H-benzo[e][1,4]diazepin-2(3H)-one
(S)-N-((2S,4S,5S)-5-(2-(2,6-dimethylphenoxy)acetamido)-4-hydroxy-1,6-diphenylhexan-2-yl)-3-methyl-2-(2-oxo-tetrahydropyrimidin-1(2H)-yl)butanamide
1172-18-5 (di-hydrochloride)
17617-23-1
191044-EP2275420A1
191044-EP2280008A2
2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-1-(2-(diethylamino)ethyl)-5-(o-fluorophenyl)-
2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1,3-dihydro-
2H-1,4-Benzodiazepin-2-one, 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-
2H-1,4-Benzodiazepin-2-one, 7-chloro-1-[2-(diethylamino)ethyl]-5-(o-fluorophenyl)-1,3-dihydro-
36105-20-1 (mono-hydrochloride)
5-24-04-00322 (Beilstein Handbook Reference)
617F231
7-chloranyl-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one
7-Chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one
7-Chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1H-1,4-benzodiazepin-2(3H)-one
7-Chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1H-benzo[e][1,4]diazepin-2(3H)-one
7-chloro-1-(2-diethylaminoethyl)-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one
7-Chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one
7-Chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one #
7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one
7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one
7-Chloro-1-[2-(diethylamino)ethyl]-5-(o-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one
A812156
AC1L1FU2
AKOS015889971
AN-5395
BRN 0767925
C-21488
CAS-17617-23-1
CC-28512
CHEBI:5128
CHEMBL968
D00329
Dalmadorm
Dalmane-R
DB00690
DEA No. 2767
DSSTox_CID_3071
DSSTox_GSID_23071
DSSTox_RID_76863
DTXSID1023071
EINECS 241-591-7
Felison
Felmane
FL7
Flunox
flurazepam
Flurazepam (JAN/INN)
Flurazepam [INN:BAN:JAN]
Flurazepam 0.1 mg/ml in Methanol
Flurazepam 1.0 mg/ml in Methanol
Flurazepam HCL
Flurazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
Flurazepam-D4 solution, 100 mug/mL in methanol, certified reference material
Flurazepamum
Flurazepamum [INN-Latin]
FT-0630442
GTPL7188
HSDB 3085
IHP475989U
Insumin
Insumin (TN)
LS-34188
NCGC00164573-01
NCGC00164573-02
Noctosom
Paxane
Ro 56901/3
Ro-5-6901
Ro-5-6901/3
Ro-56901
SAADBVWGJQAEFS-UHFFFAOYSA-N
SCHEMBL29793
Somnol
Stauroderm
Tox21_112201
Tox21_112201_1
UNII-IHP475989U
Valdorm
ZINC537752

US Patents and Regulatory Information for DALMANE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharm Intl DALMANE flurazepam hydrochloride CAPSULE;ORAL 016721-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Valeant Pharm Intl DALMANE flurazepam hydrochloride CAPSULE;ORAL 016721-002 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DALMANE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharm Intl DALMANE flurazepam hydrochloride CAPSULE;ORAL 016721-001 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
Valeant Pharm Intl DALMANE flurazepam hydrochloride CAPSULE;ORAL 016721-002 Approved Prior to Jan 1, 1982   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Dow
Colorcon
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.